

Special Issue

Gene and Cell Therapy for Cancers

Message from the Guest Editor

Due to the heterogenous nature of cancer cells both among and within individual tumors, canonical cell and gene therapy approaches over the last few decades have focused on non-genetic approaches, such as enhancing cancer cell transduction, interfering with attributes of tumor physiology, and broad-based immunotherapy approaches. With the completion of The Cancer Genome Atlas Project, molecular characterization data are now publicly available for 33 different tumor types and contain more than 20,000 individual primary tumor samples. The availability of these data presents an intriguing and exciting opportunity for the broader cell and gene therapy community to identify common aberrant signaling networks in multiple tumor types and explore novel molecular-based targets for the development of potential therapeutics. This Special Issue welcomes all studies highlighting the potential for these new approaches and molecular targets for use in cancer gene and cell therapy applications.

Guest Editor

Dr. Jacquelyn J. Bower

Department of Ophthalmology, University of North Carolina, Chapel Hill, NC, USA

Deadline for manuscript submissions

31 July 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/176180

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)